Biotech IV Monitor

KYMR — Kymera Therapeutics Inc.

$9.1B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Kymera Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is June 2027.

Next readoutJune 2027in ~7 months
Upcoming readouts3none in Phase 3
Market cap$9.1B
Cash & investments$1.65B~12 quarters at last loss rate
Recent 8-K filings1latest 2026-10-29

Upcoming readouts

Phase 2 KT-621
Atopic Dermatitis · NCT07217015
June 2027
Ongoing
Phase 2 KT-621
Eosinophilic Asthma · NCT07323654
December 2027
Recruiting
Phase 2 KT-621
Asthma (Diagnosis) · NCT07677059
December 2028
Recruiting

Cash position

Kymera Therapeutics Inc. reported $1.65B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $132M; at that rate the cash would last about 12 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-10-29

Companies working on similar indications

Discussion

No messages yet. If you follow KYMR, you can start the conversation.
Track KYMR in real time
See live implied volatility for KYMR and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on KYMR
Contact — questions or corrections about KYMR: dukeupt@gmail.com